Multifocal motor neuropathy as a mimic of amyotrophic lateral sclerosis: Serum neurofilament light chain as a reliable diagnostic biomarker

• Published in: Muscle & nerve Vol. 69; no. 4; pp. 422 - 427
• Main Authors: Kleinveld, Vera E. A., Keritam, Omar, Horlings, Corinne G. C., Cetin, Hakan, Wanschitz, Julia, Hotter, Anna, Zirch, Laura S., Zimprich, Fritz, Topakian, Raffi, Müller, Petra, Oel, Dierk, Quasthoff, Stefan, Erdler, Marcus, Rauschka, Helmut, Grinzinger, Susanne, Jecel, Julia, Gaulhofer, Petra, Castek, Barbara, Stadler, Klaus, Löscher, Wolfgang N.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.04.2024; Wiley Subscription Services, Inc
• Subjects: Amyotrophic lateral sclerosis; biomarker; Biomarkers; diagnosis; Medical diagnosis; multifocal motor neuropathy; neurofilament; Progressive motor neuropathy; diagnosis; multifocal motor neuropathy; biomarker; neurofilament; amyotrophic lateral sclerosis
• ISSN: 0148-639X; 1097-4598; 1097-4598
• DOI: 10.1002/mus.28054

Introduction/Aims The clinical presentation of multifocal motor neuropathy (MMN) may mimic early amyotrophic lateral sclerosis (ALS) with predominant lower motor neuron (LMN) involvement, posing a diagnostic challenge. Both diseases have specific treatments and prognoses, highlighting the importance of early diagnosis. The aim of this study was to assess the diagnostic value of serum neurofilament light chain (NfL) in differentiating MMN from LMN dominant ALS. Methods NfL was measured in serum in n = 37 patients with MMN and n = 37 age‐ and sex‐matched patients with LMN dominant ALS, to determine the diagnostic accuracy. Clinical and demographic data were obtained at the time of NfL sampling. Results Serum NfL concentration was significantly lower in MMN patients compared to ALS patients (mean 20.7 pg/mL vs. 59.4 pg/mL, p < .01). NfL demonstrated good diagnostic value in discriminating the two groups (AUC 0.985 [95% CI 0.963–1.000], sensitivity 94.6%, specificity 100%, cut‐off 44.00 pg/mL). Discussion NfL could be a helpful tool in differentiating MMN from LMN dominant ALS in those patients in whom electrophysiological and clinical examinations remain inconclusive early in the diagnostic process.